Erratum: Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response (Clinical pharmacology and Therapeutics (2011) 90 (568-574) DOI: 10.1038/clpt.2011.194);Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 4, 2011, Pages 568-574

  Lewis, J P ^a   Fisch, A S ^a   Ryan, K ^a   O'Connell, J R ^a   Gibson, Q ^a   Mitchell, B D ^a   Shen, H ^a   Tanner, K ^a   Horenstein, R B ^a   Pakzy, R ^b   Tantry, U S ^b   Bliden, K P ^b   Gurbel, P A ^b   Shuldiner, A R ^a,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^c BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARYLDIALKYLPHOSPHATASE 1; CLOPIDOGREL; CYTOCHROME P450 2C19; EPTIFIBATIDE; HEPARIN; HIRULOG;

ANTICOAGULANT THERAPY; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; ENZYME ACTIVITY; FOLLOW UP; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENOTYPE; HUMAN; LOADING DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 80052969477     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.17     Document Type: Erratum

References (30)

1. Kushner, F.G. et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Catheter. Cardiovasc. Interv. 74, E25-E68 (2009).
2. King, S.B. 3rd et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 117, 261-295 (2008).
3. Feher, G. et al. Clinical importance of aspirin and clopidogrel resistance. World J. Cardiol. 2, 171-186 (2010).
4. Woo, K.S. et al. Determination of the prevalence of aspirin and clopidogrel resistances in patients with coronary artery disease by using various plateletfunction tests. Korean J. Lab. Med. 30, 460-468 (2010).
5. Gurbel, P.A., Bliden, K.P., Hayes, K.M., Yoho, J.A., Herzog, W.R. & Tantry, U.S. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J. Am. Coll. Cardiol. 45, 1392-1396 (2005). (Pubitemid 40615608)
6. Hochholzer, W. et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111, 2560-2564 (2005). (Pubitemid 40740853)
7. Serebruany, V.L., Steinhubl, S.R., Berger, P.B., Malinin, A.I., Bhatt, D.L. & Topol, E.J. Variability in platelet responsiveness to clopidogrel among 544 individuals. J. Am. Coll. Cardiol. 45, 246-251 (2005). (Pubitemid 40094733)
8. Brandt, J.T. et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb. Haemost. 5, 2429-2436 (2007). (Pubitemid 350154353)
9. Shuldiner, A.R. et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302, 849-857 (2009).
10. Mega, J.L. et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360, 354-362 (2009).
11. Hulot, J.S. et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108, 2244-2247 (2006).
12. Frere, C. et al. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am. J. Cardiol. 101, 1088-1093 (2008).
13. Mega, J.L. et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304, 1821-1830 (2010).
14. Hulot, J.S. et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J. Am. Coll. Cardiol. 56, 134-143 (2010).
15. Simon, T. et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360, 363-375 (2009).
16. Sentí, M., Tomás, M., Marrugat, J. & Elosua, R. Paraoxonase1-192 polymorphism modulates the nonfatal myocardial infarction risk associated with decreased HDLs. Arterioscler. Thromb. Vasc. Biol. 21, 415-420 (2001). (Pubitemid 32199124)
17. T urban, S. et al. A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin. Atherosclerosis 154, 633-640 (2001). (Pubitemid 32232160)
18. Bhattacharyya, T. et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299, 1265-1276 (2008). (Pubitemid 351439073)
19. Bouman, H.J. et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat. Med. 17, 110-116 (2011).
20. Banerjee, I. Relationship between Paraoxonase 1 (PON1) gene polymorphisms and susceptibility of stroke: a meta-analysis. Eur. J. Epidemiol. 25, 449-458 (2010).
21. T hyagarajan, B. et al. Factors associated with paraoxonase genotypes and activity in a diverse, young, healthy population: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Clin. Chem. 54, 738-746 (2008). (Pubitemid 351573711)
22. Zhang, B. et al. Paraoxonase (Pon1) Q192R polymorphism and serum Pon1 activity in diabetic patients on maintenance hemodialysis. Clin. Nephrol. 60, 257-265 (2003). (Pubitemid 37258849)
23. Flekac, M., Skrha, J., Zídková, K., Lacinová, Z. & Hilgertová, J. Paraoxonase 1 gene polymorphisms and enzyme activities in diabetes mellitus. Physiol. Res. 57, 717-726 (2008).
24. Gurbel, P.A., Antonino, M.J. & Tantry, U.S. Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. Expert Opin. Drug Metab. Toxicol. 5, 989-1004 (2009).
25. T renk, D. et al. Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement. Circ. Cardiovasc. Genet. (2011); e-pub ahead of print 11 June 2011.
26. Sibbing, D. et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur. Heart J. 32, 1605-1613 (2011).
27. Gurbel, P.A., Bliden, K.P., Hiatt, B.L. & O'Connor, C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107, 2908-2913 (2003). (Pubitemid 36736631)
28. Antman, E.M. et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 117, 296-329 (2008).
29. Applegate, R.J., Sacrinty, M.T., Little, W.C., Santos, R.M., Gandhi, S.K. & Kutcher, M.A. Incidence of coronary stent thrombosis based on academic research consortium definitions. Am. J. Cardiol. 102, 683-688 (2008).
30. Bonello, L. et al. Consensus and future directions on the definition of high ontreatment platelet reactivity to adenosine diphosphate. J. Am. Coll. Cardiol. 56, 919-933 (2010).